The Daily Scan

August 13, 2018

Last Updated: 8:55 AM EST 

Litigation 

  • Two Lowell-based physicians have agreed to settle with the U.S. Attorney’s Office to resolve allegations of improper dispensing of controlled substances and improper billing. H.K.D. Treatment Options and Dr. Hung K. Do have agreed to pay $23,000 to settle claims of improper billing of medical services under the Controlled Substances Act and the False Claims Act. Additionally, a physician employed by H.K.D. has agreed to pay a $12,500 civil penalty for issuing invalid prescriptions for controlled substances under the Controlled Substances Act. It is alleged that, under the direction of Dr. Hung K. Do, hundreds of blank prescriptions were signed for use by unsupervised staff, additionally, an unsupervised non-physician staff member issued over 600 prescriptions for controlled substances. United States Attorney Andrew E. Lelling commented, "ensuring the proper handling of prescriptions is a critical part of our ongoing efforts to maintain patient safety and prevent drug diversion, our success in fighting the opioid crisis depends on the diligence of prescribers in ensuring that those seeking addiction treatment receive proper medical supervision.” (Justice.gov

  • United States Attorney for the District of Connecticut, announced that Jeffery Pearlman, 51, of Edgewood, N.J., pleaded guilty before U.S. District Judge in New Haven to engaging in a kickback scheme that defrauded federal healthcare programs. Pearlman has admitted that he and sales representatives he managed induced certain physicians, registered nurses and physician assistants to prescribe Subsys by paying them to participate in numerous sham "Speaker Programs." This investigation was conducted by the U.S. Department of Health and Human Services Office of the Inspector General and the FBI. (Justice.gov

  • It is alleged that from January 7, 2009 through May 2, 2012, the medical practice of Dr. Donald Chamberlin and Karen Chamberlin, billed Medicare, Tennessee Medicaid (TennCare), and the Federal Employees Health Benefit Program (FEHBP) for foreign-sourced anticancer drugs not approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States. The Chamberlin's have paid $428,700, to resolve state and federal False Claims Act allegations. “Administering oncology drugs manufactured in other countries and not approved by the FDA, risks the safety of our citizens,” said U.S. Attorney J. Douglas Overbey. (Justice.gov

  • A grand jury has returned an indictment against Adam Gallardo Arrendondo, 56, of Waxahachie, Texas, charging him with Illegal Remuneration for Health Care Referrals. Arrendondo is alleged to have solicited and received checks in exchange for referring compounding prescriptions paid for by federal programs. United States Attorney Shores commented, “illegal payment for health care referrals undermines the integrity of our health care system. The U.S. Attorney’s Office will bring to justice those who engage in health care fraud by exploiting programs that provide care for millions of Americans.” (Justice.gov

Research

  • The U.S. Government Accountability Office has released research on the National Institutes of Health and the action needed to ensure workforce diversity strategic goals are achieved. The National Institutes of Health plays a key role in biomedical research to reduce illness and lengthen life. It has its own scientific staff but more than 80% of its budget goes to researchers working in universities and other institutions. NIH has a diversity strategic plan but lacks certain measures of plan progress. the GAO recommended it develop these measures and assess plan progress. (GAO.gov, Full Report

Private Sector 

  • The Patients For Affordable Drugs is an independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs. The founder has released the following statement on CMS Medicare advantage policy change, “I appreciate Secretary Azar’s work to curb rising drug prices. Today’s action to give Medicare Advantage plans greater leverage in negotiations with drug corporations is a small but positive step in Part B. As a patient, I understand concerns about the potential misuse of step therapy, but as long as patients are protected with a timely and workable appeals process, allowing step therapy in Medicare Advantage is a step I can support. I hope that moving forward, announcements will lower list prices and generate greater savings than today’s news.” (Patientsforaffordabledrugs.org

 

 

 

 

 

 

 

Please reload

Our Recent Posts

The Weekly Scan

April 26, 2019

The Weekly Scan

April 12, 2019

The Weekly Scan

April 5, 2019

1/1
Please reload

Tags

Please reload

 

©2018 by FHAS Inc.

1 PPG Place, 31st Floor,

Pittsburgh, PA 15222